- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Central precocious puberty
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 742KB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 150KB)
Leuprorelin acetate – July 2022
Leuprorelin acetate: Suspension for subcutaneous injection (modified release) containing 45 mg of leuprorelin acetate; Eligard® 6 month
Last updated
28 October 2022